Drug Type Biosimilar, Hormone |
Synonyms Ublin, 联邦优倍灵 |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (14 Jul 2021), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 1 | China | 14 Jul 2021 | |
Diabetes Mellitus, Type 2 | China | 14 Jul 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Phase 1 | China | 04 Mar 2016 |